Zununi Vahed Sepideh, Poursadegh Zonouzi Ahmad, Ghanbarian Hossein, Ghojazadeh Morteza, Samadi Nasser, Omidi Yadollah, Ardalan Mohammadreza
Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Islamic Republic of Iran.
Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Islamic Republic of Iran.
Int Urol Nephrol. 2017 Sep;49(9):1681-1689. doi: 10.1007/s11255-017-1602-2. Epub 2017 Apr 28.
The discovery of circulating microRNAs (miRNAs), as potential noninvasive diagnostic biomarkers, has opened new avenues of research for identifying patients with chronic failure in renal transplantation. The present study aimed to investigate the expression levels of four immune-related miRNAs (miR-21, miR-31, miR-142-3p and miR-155) in plasma samples of renal recipients.
The plasma expression levels of the miRNAs were evaluated by quantitative real-time PCR (qPCR) in 53 renal recipients with long-term stable allograft function, SGF (N = 27), and with biopsy-proven interstitial fibrosis and tubular atrophy (IFTA) (N = 26) and also healthy controls (N = 15). The possible correlation between clinical parameters and the circulating miRNAs and the receiver-operating characteristic (ROC) analysis were performed.
Our results showed that expression of miR-21 (p = 0.023), miR-142-3p (p = 0.048) and miR-155 (p = 0.005) was significantly upregulated in plasma samples of recipients with IFTA in comparison with SGF and healthy control groups. Concentration of miR-21 (∆Ct value) in plasma was negatively correlated with creatinine (r = -0.432, p = 0.028) and positively correlated with eGFR (r = 0.423, p = 0.031). The multivariate ROC curve analysis indicated that miR-21, miR-142-3p and miR-155 in plasma samples could discriminate almost most of the IFTA patients (area under curve = 0.802, sensitivity = 81%, specificity = 92%).
Our data suggested that altered expression of miR-21, miR-142-3p and miR-155 in plasma samples may be associated with renal dysfunction and can be used for graft monitoring.
循环微RNA(miRNA)作为潜在的非侵入性诊断生物标志物的发现,为识别肾移植慢性功能衰竭患者开辟了新的研究途径。本研究旨在调查肾移植受者血浆样本中四种免疫相关miRNA(miR-21、miR-31、miR-142-3p和miR-155)的表达水平。
通过定量实时聚合酶链反应(qPCR)评估53例肾移植受者血浆中miRNA的表达水平,这些受者具有长期稳定的移植肾功能,即稳定移植肾功能组(SGF,n = 27),以及经活检证实存在间质纤维化和肾小管萎缩(IFTA)的患者(n = 26),还有健康对照组(n = 15)。进行了临床参数与循环miRNA之间的可能相关性分析以及受试者操作特征(ROC)分析。
我们的结果显示,与SGF组和健康对照组相比,IFTA受者血浆样本中miR-21(p = 0.023)、miR-142-3p(p = 0.048)和miR-155(p = 0.005)的表达显著上调。血浆中miR-21的浓度(∆Ct值)与肌酐呈负相关(r = -0.432,p = 0.028),与估算肾小球滤过率(eGFR)呈正相关(r = 0.423,p = 0.031)。多变量ROC曲线分析表明,血浆样本中的miR-21、miR-142-3p和miR-155几乎可以区分大多数IFTA患者(曲线下面积 = 0.802,敏感性 = 81%,特异性 = 92%)。
我们的数据表明,血浆样本中miR-21、miR-142-3p和miR-155表达的改变可能与肾功能障碍有关,可用于移植监测。